CA2214131A1 - Trisubstituted phenyl derivatives - Google Patents

Trisubstituted phenyl derivatives

Info

Publication number
CA2214131A1
CA2214131A1 CA002214131A CA2214131A CA2214131A1 CA 2214131 A1 CA2214131 A1 CA 2214131A1 CA 002214131 A CA002214131 A CA 002214131A CA 2214131 A CA2214131 A CA 2214131A CA 2214131 A1 CA2214131 A1 CA 2214131A1
Authority
CA
Canada
Prior art keywords
phenyl derivatives
trisubstituted phenyl
trisubstituted
inflammatory
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002214131A
Other languages
French (fr)
Other versions
CA2214131C (en
Inventor
Peter Nussbaumer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9505080.3A external-priority patent/GB9505080D0/en
Priority claimed from GBGB9505858.2A external-priority patent/GB9505858D0/en
Priority claimed from GBGB9526593.0A external-priority patent/GB9526593D0/en
Application filed by Individual filed Critical Individual
Publication of CA2214131A1 publication Critical patent/CA2214131A1/en
Application granted granted Critical
Publication of CA2214131C publication Critical patent/CA2214131C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/64—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Abstract

The invention concerns compounds of formula (I), wherein the substituents have various meanings, and their use in the prevention or treatment of inflammatory and proliferative skin diseases and cancer.
CA002214131A 1995-03-14 1996-03-14 Trisubstituted phenyl derivatives Expired - Fee Related CA2214131C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9505080.3A GB9505080D0 (en) 1995-03-14 1995-03-14 Organic compounds
GB9505080.3 1995-03-14
GB9505858.2 1995-03-23
GBGB9505858.2A GB9505858D0 (en) 1995-03-23 1995-03-23 Organic Compounds
GBGB9526593.0A GB9526593D0 (en) 1995-12-28 1995-12-28 Organic compounds
GB9526593.0 1995-12-28
PCT/EP1996/001116 WO1996028430A1 (en) 1995-03-14 1996-03-14 Trisubstituted phenyl derivatives

Publications (2)

Publication Number Publication Date
CA2214131A1 true CA2214131A1 (en) 1996-09-19
CA2214131C CA2214131C (en) 2009-06-23

Family

ID=27267624

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002214131A Expired - Fee Related CA2214131C (en) 1995-03-14 1996-03-14 Trisubstituted phenyl derivatives

Country Status (24)

Country Link
US (1) US5990116A (en)
EP (1) EP0815087B1 (en)
JP (1) JP3194963B2 (en)
KR (1) KR100437580B1 (en)
CN (1) CN1101386C (en)
AT (1) ATE208763T1 (en)
AU (1) AU704544B2 (en)
BR (1) BR9607240A (en)
CA (1) CA2214131C (en)
CZ (1) CZ289944B6 (en)
DE (1) DE69616993T2 (en)
DK (1) DK0815087T3 (en)
ES (1) ES2168463T3 (en)
FI (1) FI120537B (en)
HK (1) HK1014440A1 (en)
HU (1) HUP9801828A3 (en)
MX (1) MX9707022A (en)
NO (1) NO310356B1 (en)
NZ (1) NZ304291A (en)
PL (1) PL185875B1 (en)
PT (1) PT815087E (en)
RU (1) RU2164224C2 (en)
SK (1) SK282155B6 (en)
WO (1) WO1996028430A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
JP3270834B2 (en) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク Heteroaromatic bicyclic derivatives useful as anticancer agents
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
UA74803C2 (en) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
KR100819716B1 (en) * 2000-04-07 2008-04-07 칫소가부시키가이샤 Novel diamino compounds, polymers prepared from the same, and varnishes, aligning films and liquid crystal display elements using the polymers
WO2003032999A1 (en) * 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
US7053216B2 (en) 2001-11-19 2006-05-30 Iconix Pharmaceuticals, Inc. Modulators of Rho C activity
CA2491820A1 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
EP1534274A1 (en) * 2002-07-17 2005-06-01 Warner-Lambert Company LLC Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
AU2003249539A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
GB0319497D0 (en) * 2003-08-19 2003-09-17 Novartis Ag Organic compounds
SE0400234D0 (en) * 2004-02-06 2004-02-06 Active Biotech Ab New compounds, methods for their preparation and use thereof
US20080044439A1 (en) * 2004-03-11 2008-02-21 David Nathaniel E Compositions and Methods for Preventing and Treating Skin and Hair Conditions
US20080031898A1 (en) * 2004-03-26 2008-02-07 David Nathaniel E Compositions and methods to increase the effect of a neurotoxin treatment
GB0412769D0 (en) * 2004-06-08 2004-07-07 Novartis Ag Organic compounds
CA2574095C (en) 2004-08-04 2013-05-21 Meiji Seika Kaisha, Ltd. Quinoline derivatives and insecticide comprising thereof as active ingredient
WO2008044688A1 (en) * 2006-10-11 2008-04-17 Daiichi Sankyo Company, Limited Urea derivative
EP2118051B1 (en) 2007-02-06 2011-05-04 Chelsea Therapeutics, Inc. New compounds, methods for their preparation and use thereof
EP3762379A1 (en) 2018-03-07 2021-01-13 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
WO2021026672A1 (en) * 2019-08-09 2021-02-18 Novartis Ag Heterocyclic wdr5 inhibitors as anti-cancer compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5651423A (en) * 1979-09-13 1981-05-09 Wellcome Found Antiviral agent
CA1219587A (en) * 1981-12-14 1987-03-24 Norman P. Jensen Hydroxybenzylaminobenzenes as anti-inflammatory agents
NZ213986A (en) * 1984-10-30 1989-07-27 Usv Pharma Corp Heterocyclic or aromatic compounds, and pharmaceutical compositions containing such
WO1988003806A1 (en) * 1986-11-19 1988-06-02 Chemex Pharmaceuticals, Inc. Pharmacologically active compositions of catecholic butanes with zinc
EP0289506A4 (en) * 1986-11-19 1990-12-12 Chemex Pharmaceuticals, Inc. Lipoxygenase inhibitors
US4851423A (en) * 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
US5272167A (en) * 1986-12-10 1993-12-21 Schering Corporation Pharmaceutically active compounds
AU6062590A (en) * 1989-07-07 1991-02-06 Schering Corporation Pharmaceutically active compounds
HUT60458A (en) * 1991-02-01 1992-09-28 Sandoz Ag Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
ATE159009T1 (en) * 1991-05-10 1997-10-15 Rhone Poulenc Rorer Int BIS MONO- AND BICYCLIC ARYL AND HETEROARYL DERIVATIVES WITH AN INHIBITING EFFECT ON THE EGF AND/OR PDGF RECEPTOR TYROSINKINASE
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9121943D0 (en) * 1991-10-16 1991-11-27 Sandoz Ltd Organic compounds,processes for their production and their use
US5656643A (en) * 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase

Also Published As

Publication number Publication date
CN1101386C (en) 2003-02-12
PL185875B1 (en) 2003-08-29
FI973440A0 (en) 1997-08-21
BR9607240A (en) 1997-11-11
FI973440A (en) 1997-10-24
JP3194963B2 (en) 2001-08-06
KR100437580B1 (en) 2004-07-16
CN1183774A (en) 1998-06-03
RU2164224C2 (en) 2001-03-20
ES2168463T3 (en) 2002-06-16
HK1014440A1 (en) 1999-09-30
SK124597A3 (en) 1998-01-14
DE69616993D1 (en) 2001-12-20
FI120537B (en) 2009-11-30
HUP9801828A2 (en) 1999-03-29
NO974118L (en) 1997-09-08
NO974118D0 (en) 1997-09-08
SK282155B6 (en) 2001-11-06
CA2214131C (en) 2009-06-23
PL322134A1 (en) 1998-01-05
CZ289944B6 (en) 2002-04-17
NO310356B1 (en) 2001-06-25
ATE208763T1 (en) 2001-11-15
KR19980703049A (en) 1998-09-05
AU5144396A (en) 1996-10-02
AU704544B2 (en) 1999-04-29
MX9707022A (en) 1998-06-30
NZ304291A (en) 1999-01-28
EP0815087B1 (en) 2001-11-14
DK0815087T3 (en) 2002-03-11
HUP9801828A3 (en) 2001-02-28
US5990116A (en) 1999-11-23
PT815087E (en) 2002-04-29
EP0815087A1 (en) 1998-01-07
DE69616993T2 (en) 2002-07-04
JPH11503412A (en) 1999-03-26
WO1996028430A1 (en) 1996-09-19
CZ286997A3 (en) 1997-12-17

Similar Documents

Publication Publication Date Title
CA2214131A1 (en) Trisubstituted phenyl derivatives
BG105270A (en) Tetrahydropyridoethers
HK1026909A1 (en) Substituted phenyl derivatives, their preparation and use
CY2538B1 (en) Tetrahydropyrido compounds
AU6613896A (en) Chemical compounds
AU1044500A (en) Imidazonaphthyridines
CA2267309A1 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections
MY135559A (en) Acylated aminoalkanimidazoles and - triazoles
BG103260A (en) The application of 1-hydroxy-2-pyridons for the treatment of seborrheic dermatitis
MX9700624A (en) Imidazopyridine-azolidinones.
AU1278600A (en) Novel therapeutic application of nicergoline
MY116727A (en) Tetrahydropyrido compounds
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
AU2360595A (en) Use of benzylidene-malononitrile derivates for the treatment of leukemia
RU95118900A (en) Antitumor agent
RU95100512A (en) OINTMENT FOR TREATMENT OF SKIN DISEASES

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed